IART Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Integra Lifesciences Holdings Corp (IART) is not a good buy for a beginner, long-term investor at this moment. The stock's technical indicators are bearish, financial performance is weak, and there are no strong positive catalysts or trading signals to support an immediate investment. The investor should wait for more favorable conditions or a clearer turnaround in the company's performance.
The stock is in a bearish trend with the MACD histogram at -0.129 (negatively expanding), RSI_6 at 18.741 (oversold), and moving averages indicating a downtrend (SMA_200 > SMA_20 > SMA_5). Key support is at 10.06, with resistance at 12.081. The stock is trading near its support level, but the overall trend remains negative.
NULL. No significant news, trading trends, or congressional activity to act as a positive catalyst.
Weak financial performance in Q4 2025 with revenue down -1.74% YoY, net income down -108.77% YoY, and EPS down -108.00% YoY. Analysts have lowered price targets, and the stock has a 50% chance to decline further in the short term.
In Q4 2025, revenue dropped to $434.93M (-1.74% YoY), net income dropped to -$1.70M (-108.77% YoY), EPS dropped to -$0.02 (-108.00% YoY), and gross margin fell to 57.02% (-3.71% YoY). These figures indicate deteriorating financial health.
Analysts have a negative outlook on the stock. JPMorgan lowered the price target to $11 from $13 with an Underweight rating, and Wells Fargo lowered the price target to $12 from $13 with an Equal Weight rating. Analysts highlight operational challenges and back-half-loaded revenue guidance for 2026.
